In Metastatic Prostate Cancer, Radiographic PFS Associated with Survival
the Cancer Therapy Advisor take:
According to a new study published by the Journal of Clinical Oncology, researchers have found that radiographic progression-free survival (rPFS) was highly consistent and associated with overall survival in a randomized trial of abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Because progression-free survival in mCRPC studies has been inconsistently defined and poorly associated with overall survival, researchers sought to study a reproducible quantitative definition of rPFS to test for an association with overall survival.
Researchers defined rPFS as "≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 12 weeks after random assignment, and/or progression in nodes or viscera on cross-sectional imaging, or death."
Results showed hazard ratios of 0.49 (95% CI: 0.41 - 0.60; P <0.001) and 0.53 (95% CI: 0.45 - 0.62; P < 0.001). The Spearman's correlation coefficient between rPFS and overall survival was 0.72.
The findings suggest that rPFS should be further developed as an intermediate endpoint in trials studying patients with mCRPC.
Radiographic progression-free survival was highly associated with overall survival in metastatic castration-resistant prostate cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC